避免新型药物耐药发展:开放研究方向
该叙述性综述检索PubMed-MEDLINE近5年英文文献,总结延缓新型抗菌药物耐药发展的抗菌与非抗菌策略。优化药代动力学/药效学靶点(如持续输注、治疗药物监测)可能有助于预防耐药;联合治疗相较单药治疗的常规获益当前证据不足;粪菌移植、噬菌体疗法及主动/被动免疫等非抗菌干预在高危人群中展现潜力。
要点
- 优化PK/PD靶点、持续输注与治疗药物监测可能帮助预防耐药。
- 新型药物治疗中联合方案较单药的常规获益未被证实,相关研究样本小、质量有限。
- 粪菌移植、噬菌体疗法和免疫接种可作为高危人群的辅助耐药防控工具。
核心结论
- 预防新型β-内酰胺/β-内酰胺酶抑制剂组合耐药目前依赖优化给药与输注策略。
- 联合方案获益仍不确定,需以耐药出现为终点进一步研究。
- 非抗菌干预在高危环境中具前景,应纳入更广泛的耐药预防框架。
研究设计与样本
- 叙述性综述;检索PubMed-MEDLINE近5年英文文献。
- 研究对象为多重耐药革兰阴性菌,尤其碳青霉烯耐药或难治性耐药表型。
主要发现
- 达成激进的联合PK/PD靶点可能有助于预防耐药,支持手段包括时间依赖性药物持续输注与治疗药物监测。
- 当前证据未显示新型药物联合治疗较单药治疗有常规获益,但研究规模与质量有限,耐药出现罕作为主要终点。
- 粪菌移植、噬菌体疗法、主动或被动免疫可能降低多重耐药革兰阴性菌负荷,尤其在高危人群。
临床怎么用
- 对新型β-内酰胺/β-内酰胺酶抑制剂组合应优先优化剂量与输注策略。
- 不应常规以联合治疗替代单药治疗来预防耐药,需个体化评估。
- 在高危人群可考虑将非抗菌干预作为辅助耐药防控措施。
局限性
- 为叙述性综述,未报告系统检索筛选流程与定量合并。
- 现有联合治疗研究规模小、质量有限,耐药出现罕为主要终点。
- 非抗菌策略的临床获益与整合方式仍需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The spread of multidrug-resistant gram-negative bacteria, particularly those with carbapenem-resistant or difficult-to-treat resistance phenotypes, is a major public health threat. New agents offer potent therapeutic options but carry the challenge of preserving their effectiveness against resistance. OBJECTIVES: This narrative review summarizes antimicrobial and non-antimicrobial strategies to prevent or mitigate resistance development to novel agents. SOURCES: We searched PubMed-MEDLINE for English-language articles published in the last 5 years. CONTENT: Among antimicrobial strategies, we reviewed the role of optimising pharmacokinetic/pharmacodynamic targets for novel β-lactam/β-lactamase inhibitor combinations and the impact of combination vs. monotherapy regimens. Achieving aggressive joint pharmacokinetic/pharmacodynamic targets may help prevent resistance, supported by approaches such as continuous infusion of time-dependent agents and therapeutic drug monitoring. Current evidence does not demonstrate a routine benefit of combination therapy over monotherapy for novel drugs; however, available studies are limited in size and quality, and resistance emergence has rarely been a primary endpoint. Non-antimicrobial strategies reviewed include faecal microbiota transplantation, phage therapy, and active or passive immunisation. These approaches may reduce the burden of multidrug-resistant gram-negative bacteria, particularly in high-risk populations such as immunocompromised patients, those undergoing invasive procedures, or patients with foreign bodies. By lowering pathogen load and transmission, these interventions could enhance the effectiveness of current drugs and limit further resistance development. IMPLICATIONS: Prevention of resistance to novel β-lactam/β-lactamase inhibitor combinations currently relies on optimized dosing and infusion strategies. The benefit of combination regimens remains uncertain and warrants further investigation, ideally with resistance emergence as a defined endpoint and addressed with appropriate analysis. Non-antimicrobial interventions show promise as adjunctive tools in high-risk settings and merit integration into broader resistance prevention frameworks.
引用
- Rinaldi M, Gatti M, Giannella M, et al. Avoiding resistance development to newer drugs: open research lines. Clin Microbiol Infect. 2025. PMID: 41241177. doi:10.1016/j.cmi.2025.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。